Trakhtenberg A Kh, Zakharchenkov A V, Zhiglov M A, Glagolev A N, Kovalev V N, Amiraliev M A, Barchuk A S, Malay E F, Vidyak I V, Grigoryeva S P
P.A. Gertsen Research Institute of Oncology, Moscow, USSR.
Neoplasma. 1988;35(3):351-8.
The results of a cooperative randomized study performed in Poland, Bulgaria, Czechoslovakia, Hungary, and the Soviet Union on the treatment of lung cancer patients are presented. Three hundred and sixty patients were treated only surgically, 360 patients received combined therapy. Adjuvant chemotherapy was performed using 3 preparations (cyclophosphane, methotrexate, 5-fluorouracil) within 2-3 weeks after operation (first course) followed by another 3 courses at intervals of 8-9 weeks. The combined therapy increased the 5-year survival rate of patients with Stage III squamous cell carcinoma with thoracic lymph node metastases. Better results were achieved when 3-4 courses of adjuvant chemotherapy were performed. In patients with Stage I-II squamous cell carcinoma of the lung without regional lymph node metastases the used regimen of combined therapy had no significant effect.
本文展示了在波兰、保加利亚、捷克斯洛伐克、匈牙利和苏联开展的一项关于肺癌患者治疗的合作随机研究结果。360名患者仅接受手术治疗,360名患者接受联合治疗。辅助化疗在术后2至3周内使用3种制剂(环磷酰胺、甲氨蝶呤、5-氟尿嘧啶)进行(第一疗程),随后每隔8至9周进行另外3个疗程。联合治疗提高了伴有胸段淋巴结转移的III期鳞状细胞癌患者的5年生存率。进行3至4个疗程的辅助化疗时效果更佳。对于无区域淋巴结转移的I-II期肺鳞状细胞癌患者,所采用的联合治疗方案没有显著效果。